Ezabenlimab (BI-754091) is an anti-PD-1 monoclonal antibody (mAb) with a binding constant (Kd) of 6 nM in CHO cells.

CC Chemokine Receptor 3 Fragment II, amide

2H-1-Benzopyran-2-one, 3-(3H-imidazo[4,5-c]pyridin-2-yl)-6-methyl- is a first-in-class JMJD6 inhibitor and was shown to be able to suppress JMJD6-dependent cancer cell proliferation including cervical and liver cancer cells.